Patents by Inventor Mary B. Sliwkowski
Mary B. Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6932965Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: GrantFiled: May 22, 2002Date of Patent: August 23, 2005Assignee: Genentech, Inc.Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
-
Patent number: 6916916Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. Nucleic acid encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase.Type: GrantFiled: December 19, 2002Date of Patent: July 12, 2005Assignee: Genentech, Inc.Inventors: Thomas G. Warner, Mary B. Sliwkowski
-
Publication number: 20030166020Abstract: An isolated TGF-&bgr; supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-&bgr; supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-&bgr; supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.Type: ApplicationFiled: July 10, 2002Publication date: September 4, 2003Applicant: Genentech, Inc.Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
-
Publication number: 20030148493Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. Nucleic acid encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase.Type: ApplicationFiled: December 19, 2002Publication date: August 7, 2003Applicant: Genentech, Inc.Inventors: Thomas G. Warner, Mary B. Sliwkowski
-
Patent number: 6562588Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. Nucleic acid encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase.Type: GrantFiled: June 9, 1997Date of Patent: May 13, 2003Assignee: Genentech, Inc.Inventors: Thomas G. Warner, Mary B. Sliwkowski
-
Publication number: 20030077267Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: ApplicationFiled: May 22, 2002Publication date: April 24, 2003Applicant: Genentech, Inc.Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
-
Patent number: 6455262Abstract: An isolated TGF-&bgr; supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-&bgr; supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-&bgr; supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.Type: GrantFiled: September 21, 1993Date of Patent: September 24, 2002Assignee: Genentech, Inc.Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
-
Patent number: 6440412Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: GrantFiled: August 11, 2000Date of Patent: August 27, 2002Assignee: Genentech, Inc.Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
-
Publication number: 20020076791Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. Nucleic acid encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase.Type: ApplicationFiled: June 9, 1997Publication date: June 20, 2002Inventors: THOMAS G. WARNER, MARY B. SLIWKOWSKI
-
Publication number: 20020045207Abstract: Glycoprotein production methods and host cell lines are provided. The production methods and host cells include the functional expression of a galactosyltransferase and a sialyltransferase alone or in combination with a host cell line selected for lack of functional expression of a glycohydrolytic enzyme such as a sialidase.Type: ApplicationFiled: October 19, 1998Publication date: April 18, 2002Inventors: LYNNE A. KRUMMEN, MARY B. SLIWKOWSKI, TOM WARNER
-
Patent number: 5928915Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. DNA encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase, and the DNA is expressed in host cells transformed with the DNA.Type: GrantFiled: June 9, 1997Date of Patent: July 27, 1999Assignee: Genentech, Inc.Inventors: Thomas G. Warner, Mary B. Sliwkowski
-
Patent number: 5783433Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: GrantFiled: June 2, 1995Date of Patent: July 21, 1998Assignee: Genentech, Inc.Inventors: John Frenz, Mary B. Sliwkowski
-
Patent number: 5286654Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.Type: GrantFiled: February 3, 1993Date of Patent: February 15, 1994Assignee: Genentech, Inc.Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
-
Patent number: 5279823Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.Type: GrantFiled: June 8, 1992Date of Patent: January 18, 1994Assignee: Genentech, Inc.Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
-
Patent number: 5216126Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.Type: GrantFiled: June 19, 1991Date of Patent: June 1, 1993Assignee: Genentech, Inc.Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff